Skip to content

Ketamine: all studies

Page 426 of 449: studies 4,251 to 4,260 of 4,489, newest first. Back to the ketamine overview

Research

Salvinorina A: terpeno alucinógeno presente en Salvia divinorum Epling & Játiva

Colombia Forense April 10, 2017 Valentina Soto-Restrepo, Gonzalo Taborda Ocampo, William F. Garzón Mendez

Tema y alcance: el objetivo de esta revisión es presentar los estudios químicos que se han realizado sobre Salvia divinorum E&J en estos últimos años. Características: desde la década de 1990 hasta hoy se ha incrementado la distribución y el uso de Salvia divinorum E&J para “fines recreativos”, debido a sus efectos alucinógenos y a su fácil acceso. Sus efectos en el organismo se han relacionado...

The Subjective Response to Nitrous Oxide is a Potential Pharmaco-Endophenotype for Alcohol Use Disorder: A Preliminary Study with Heavy Drinkers.

The International Journal of Neuropsychopharmacology April 1, 2017 Katie Walsh, Ravi Das, Sunjeev K. Kamboj

Healthy people with a family history of alcohol problems show a pattern of subjective responses to alcohol that resemble those of affected probands. Studies on ketamine suggest that up-regulation of N-methyl-D-aspartate receptors (NMDARs) underlies these effects, and point to a pharmacologically-responsive endophenotype reflecting enhanced risk for alcohol-use disorders. Subjective stimulant...

What are sweet dreams made of? Analysis of psychoactive substances into “gummies”: A retrospective descriptive study

European Psychiatry April 1, 2017 Amira Trabsa, E. Monteagudo, D.d. Mariona et al. 2 citations

Introduction Although psychoactive substances has a long history in recreational settings, research on its composition has focused only on tablets, crystal and powder, even though new formulation for new psychoactive substances are readily available for users. Objectives To describe the presence of psychoactive substances and its characteristics in new formulations which had not previously been...

Accelerated Recovery of Consciousness after General Anesthesia Is Associated with Increased Functional Brain Connectivity in the High-Gamma Bandwidth

Frontiers in Systems Neuroscience March 23, 2017 Duan Li, Viviane S. Hambrecht‐Wiedbusch, George A. Mashour 33 citations

Recent data from our laboratory demonstrate that high-frequency gamma connectivity across the cortex is present during consciousness and depressed during unconsciousness. However, these data were derived from static and well-defined states of arousal rather than during transitions that would suggest functional relevance. We also recently found that subanesthetic ketamine administered during...

DOI: 10.3389/fnsys.2017.00016 (opens in new tab) Functional connectivity Consciousness Anesthesia

A KETAMIN HATÁSA A TERÁPIAREZISZTENS MAJOR DEPRESSZIÓRA

Psychologia Hungarica Caroliensis March 1, 2017 Szte BTK Pszichológiai Intézet Elte PPK Pszichológiai Intézet, Nikolett Peszeki

The effect of Ketamine on therapy resistant major depression In scientific publications we can easily find more and more research on the possible positive effects of different kinds of psychedelics, such as ketamine, for example in major depression.The aim of this paper is to present the current state of this controversial topic, starting with the invention of psychedelics, the history of using...

The fibrinolytic system: A new target for treatment of depression with psychedelics.

Medical Hypotheses March 2017 R D Idell, G Florova, A A Komissarov et al.

Current understanding of the neurobiology of depression has grown over the past few years beyond the traditional monoamine theory of depression to include chronic stress, inflammation and disrupted synaptic plasticity. Tissue plasminogen activator (tPA) is a key factor that not only promotes fibrinolysis via the activation of plasminogen, but also contributes to regulation of synaptic...

Behavioral Patterns of Psychiatric Patients Using Synthetic Cannabinoids

Journal of Addiction Research February 7, 2017

Synthetic cannabinoids (SC) are analogs of natural cannabinoids that are chemically synthesized. These compounds are used frequently in the community as illicit substances. Literature review indicates that its use is increasing due to its easy accessibility despite it being placed under Schedule I of the Synthetic Drug Abuse Prevention Act of 2012. SC is readily found in most inner urban...

Rapid Acting Antidepressants in Chronic Stress Models: Molecular and Cellular Mechanisms

Chronic Stress February 1, 2017 Brendan Hare, Sriparna Ghosal, Ronald S. Duman 69 citations

Stress-associated disorders, including depression and anxiety, impact nearly 20% of individuals in the United States. The social, health, and economic burden imposed by stress-associated disorders requires in depth research efforts to identify suitable treatment strategies. Traditional medications (e.g., selective serotonin reuptake inhibitors, monoamine oxidase inhibitors) have significant...

DOI: 10.1177/2470547017697317 (opens in new tab) Anxiety Antidepressant Monoamine oxidase Prefrontal cortex +7

“Being with a Buddha”: A Case Report of Methoxetamine Use in a United States Veteran with PTSD

Case Reports in Psychiatry January 29, 2017 Joan M. Striebel, E. Nelson, Raj K. Kalapatapu

Methoxetamine (MXE) is a ketamine analogue with a high affinity for the N-methyl-D-aspartate (NMDA) receptor. MXE is a newly emerging designer drug of abuse and is widely available through on-line sources and is not detected by routine urine drug screens. In this report, we describe a United States (US) veteran with posttraumatic stress disorder (PTSD) and heavy polysubstance use, who injected...

Investigational drugs in recent clinical trials for treatment-resistant depression

Expert Review of Neurotherapeutics January 16, 2017 Ricardo Pablo Garay, Carlos A. Zarate, Thomas Charpeaud et al. 79 citations

INTRODUCTION: The authors describe the medications for treatment-resistant depression (TRD) in phase II/III of clinical development in the EU and USA and provide an opinion on how current treatment can be improved in the near future. Areas covered: Sixty-two trials were identified in US and EU clinical trial registries that included six investigational compounds in recent phase III development...